Answer
Minjuvi (tafasitamab) is contraindicated in patients with hypersensitivity to tafasitamab or any excipient listed in section 6.1 of its Summary of Product Characteristics.
Sources for this answer
- MINJUVI 200 mg powder for concentrate for solution for infusionIncyte Biosciences UK Ltd · emc · SmPC §4.3 Contraindications · Version 13Document updated
Sources checked